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The P2X7 receptor (P2X7R) is an ATP-gated ion chan-
nel expressed by monocytes and macrophages. To di-
rectly address the role of this receptor in interleukin
(IL)-1b post-translational processing, we have gener-
ated a P2X7R-deficient mouse line. P2X7R
2/2 macro-
phages respond to lipopolysaccharide and produce lev-
els of cyclooxygenase-2 and pro-IL-1b comparable with
those generated by wild-type cells. In response to ATP,
however, pro-IL-1b produced by the P2X7R
2/2 cells is
not externalized or activated by caspase-1. Nigericin,
an alternate secretion stimulus, promotes release of
17-kDa IL-1b from P2X7R
2/2 macrophages. In response
to in vivo lipopolysaccharide injection, both wild-type
and P2X7R
2/2 animals display increases in peritoneal
lavage IL-6 levels but no detectable IL-1. Subsequent
ATP injection to wild-type animals promotes an in-
crease in IL-1, which in turn leads to additional IL-6
production; similar increases did not occur in ATP-
treated, LPS-primed P2X7R
2/2 animals. Absence of the
P2X7R thus leads to an inability of peritoneal macro-
phages to release IL-1 in response to ATP. As a result of
the IL-1 deficiency, in vivo cytokine signaling cascades
are impaired in P2X7R-deficient animals. Together these
results demonstrate that P2X7R activation can provide a
signal that leads to maturation and release of IL-1b and
initiation of a cytokine cascade.
Interleukin (IL)1-1 is a multipotential inflammatory media-
tor produced in abundance by activated monocytes and macro-
phages (1). When released from producing cells, IL-1 binds to
receptors on target cells and elicits signaling cascades leading
to the up-regulation of gene products that contribute to an
inflammatory state including matrix metalloproteinases, cy-
clooxygenase-2 (Cox-2), IL-6, and cellular adhesion molecules
(2–5). Two distinct gene products, IL-1a and IL-1b, contribute
to IL-1 biological activity (6, 7). The amino acid sequences of
IL-1a and IL-1b are ,30% identical yet these two polypeptides
bind to the same receptors on target cells (8). Human IL-1a and
IL-1b both are initially produced as 31-kDa procytokines con-
taining amino-terminal extensions; these extensions subse-
quently are removed by proteolysis. In the case of pro-IL-1a,
the propolypeptide and its 17-kDa cleavage product display
equivalent signaling activity, indicating that proteolytic cleav-
age is not necessary to generate a receptor-competent ligand
(9). In contrast, pro-IL-1b does not bind to the signaling IL-1
receptor (9), and cleavage by caspase-1 is necessary to generate
the mature 17-kDa signaling-competent form of this cytokine
(10, 11).
The two forms of IL-1 share another very unusual attribute;
both pro-IL-1a and pro-IL-1b are synthesized without a signal
sequence (7), the peptide epitope required to direct nascent
polypeptides to the endoplasmic reticulum (12). As a result,
newly synthesized pro-IL-1a and pro-IL-1b accumulate within
the cytoplasmic compartment of producing cells (13) rather
than being sequestered to the secretory apparatus. Caspase-1
also is produced as a cytosol-localized proenzyme; the 45-kDa
propolypeptide must be proteolytically processed to generate
the 20- and 10-kDa subunits that constitute the mature active
protease (11, 14, 15). In activated monocytes and macrophages,
therefore, pro-IL-1b and procaspase-1 co-exist within the cyto-
plasm. Mechanisms that control activation of procaspase-1,
and in turn cleavage of pro-IL-1b, are not well understood.
Recent studies, however, have provided evidence that proteo-
lytic processing of IL-1b and release of the mature cytokine
product extracellularly do not proceed constitutively. Rather,
the post-translational processing of pro-IL-1 requires that li-
popolysaccharide (LPS)-activated monocytes and/or macro-
phages encounter an external stimulus that promotes activa-
tion of procaspase-1, cleavage of pro-IL-1b, and release of the
17-kDa cytokine (16–18). Stimuli that function in vitro to pro-
mote IL-1 post-translational processing by LPS-activated
monocytes and/or macrophages include ATP, nigericin, cyto-
lytic T-cells, bacterial toxins, and hypotonic stress (19–24).
This requirement for a secretion stimulus is not restricted to
cells in culture; mouse peritoneal macrophages produce pro-
IL-1b in response to intraperitoneal (ip) injection of LPS, but
release little cytokine extracellularly (25). Subsequent ip injec-
tion of ATP, however, stimulates generation of large quantities
of extracellular mature IL-1b (25).
The mechanism by which ATP activates IL-1b post-transla-
tional processing is believed to involve the P2X7 purinergic
receptor (17, 18, 26, 27). Like other members of the P2X recep-
tor family, the P2X7 receptor (P2X7R) is an ATP-gated ion
channel (28–30). The P2X7R, however, demonstrates at-
tributes that clearly distinguish it from other members of the
family. For example, the P2X7R requires levels of ATP in excess
of 1 mM to achieve activation, whereas other P2X receptors
activate at ATP concentrations of #100 mM (31, 32); the higher
concentration requirement reflects, in part, the preference of
the P2X7R for ATP
42 as its ligand and the relatively low
abundance of this species in media containing physiological
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concentrations of divalent cations (e.g. Ca21 and Mg21). An
additional unique feature of the P2X7R is found in its conduct-
ance properties. All P2X receptors demonstrate non-selective
channel-like properties following ligation, but the channels
formed by the P2X7R rapidly transform to pores that allow
passage of solutes as large as 900 Da (32, 33). Molecular details
of this transformation remain to be described, but domain
swapping and deletion experiments have suggested that the
carboxyl-terminal domain of the P2X7R participates in pore
complex formation (28, 29); the carboxyl-terminal domain of
the P2X7R is significantly longer than the comparable domains
in the other P2X receptors (34). Possibly as a consequence of
this pore-like activity, continuous ligation of the P2X7 receptor
for times of .15 min can lead to cell death (35–37).
In this study we employ a genetic approach to inactivate the
P2X7R. Mice lacking the P2X7R are healthy and fertile and
demonstrate no overt phenotype. However, in contrast to their
wild-type counterparts, LPS-activated peritoneal macrophages
from P2X7R
2/2 animals fail to generate mature IL-1b when
challenged with ATP. This defect is not because of an inability
of the macrophages to produce pro-IL-1b but rather to an
inability of the cytokine producing cells to respond to the puri-
noceptor agonist. As a consequence of their inability to produce
mature IL-1b post-ATP challenge, P2X7R
2/2 animals generate
reduced quantities of IL-6 relative to their wild-type controls.
Therefore, the knockout animals establish that the P2X7R is a
necessary component of ATP-induced IL-1 post-translational
processing, and demonstrate that this receptor can serve as an
important element of an inflammatory cascade mechanism.
EXPERIMENTAL PROCEDURES
Construction of the P2X7R Targeting Vector and Generation of the
Knockout Mice—A cDNA probe specific to the mouse P2X7R gene was
synthesized by reverse transcription-polymerase chain reaction using
primers P2X7-F1 (59-CGGCGTGCGTTTTGACATCCT-39) and P2X7-R2
(59-AGGGCCCTGCGGTTCTC-39), which were designed based on the
published rat cDNA sequence of the P2X7R gene (28). Total RNA
isolated from the J774 A.1 mouse monocyte/macrophage cell line was
used as the template RNA. This polymerase chain reaction product was
401 base pairs long and was cloned and sequenced to verify that it
corresponded to the mouse P2X7R gene. The probe was used to screen a
129/Sv mouse genomic library and to isolate a single positive genomic
clone. Sequence analysis of BamHI subcloned fragments confirmed that
this clone corresponded to the mouse P2X7R gene. A targeting vector
was constructed that inserted the neomycin resistance gene from the
pJNS2 plasmid directly after the Arg505 codon, deleting from Cys506 to
Pro532, which is in the carboxyl-terminal domain of the P2X7R gene
product (38).
129/Ola-derived E14Tg2a ES cells (39) were grown, transformed, and
screened using standard methods (40). Targeted ES cells and mice
carrying the mutant allele were identified using a probe specific to a
genomic region upstream of the targeted locus. Chimeric mice derived
from targeted ES cells were mated with B6D2 (C57 BL/6 3 DBA/2 F1)
or C57BL/6 mice.
Peritoneal Macrophage Isolation—Mouse peritoneal macrophages
were harvested by injecting 5 ml of RPMI medium containing 5% FBS
into each peritoneal cavity; immediately prior to injection, the animals
were euthanized. The injected medium was dispersed throughout the
peritoneal cavity, after which a hole in the skin covering the peritoneum
was introduced and the injected fluid was recovered with the aid of a
transfer pipette. Lavage fluids from multiple animals were pooled and
the cells were collected by centrifugation (300 3 g). These cell pellets
were washed twice by centrifugation in RPMI containing 5% fetal calf
serum. A cell count was performed before the final wash.
Western Analysis—Peritoneal macrophage cell pellets were washed
once in cavitation buffer (25 mM Hepes, pH 7, 30 mM NaCl, 1 mM EDTA,
1 mM dithiothreitol, 1 mg/ml leupeptin, and 1 mg/ml pepstatin) by
centrifugation. Cell pellets then were suspended in 2.5 ml of cavitation
buffer, and the cells were disrupted by nitrogen cavitation (15 min on
ice at 750 psi). The resulting cell lysates were adjusted to 0.1% saponin,
incubated on ice for 30 min, and cell membranes subsequently were
recovered by centrifugation (50,000 rpm for 30 min at 4 °C in a Beck-
man Ti70 rotor). The membrane pellet was suspended in 2 ml of cavi-
tation buffer with the aid of a glass tube-teflon pestle homogenizer, and
an aliquot of the suspension was set aside for analysis of total protein
(Pierce, Rockford, IL). The membranes again were collected by centrif-
ugation after which the pellets were suspended in 100 ml of 23 Laemmli
sample buffer (41).
40 mg of protein were loaded into wells of a 4–20% Tris-glycine gel
(Novex, San Diego, CA), and after separation the proteins were trans-
ferred to nitrocellulose. These blots were blocked overnight at 4 °C in
13 Western blocking reagent (Roche Molecular Biochemicals, Indian-
apolis, IN) in TBS-T (10 mM Tris, pH 8, 150 mM NaCl, 0.1% Tween 20).
Blots then were incubated for 2 h at room temperature in a TBS-T
solution containing a 1:200 dilution of anti-P2X7R serum (Alomone,
Jerusalem, Israel) and 13 Western blocking reagent. Blots were
washed in TBS-T (three rinses, 5 min each) and then incubated for 1 h
with TBS-T containing a 1:2000 dilution of horseradish peroxidase-
conjugated anti-rabbit IgG (New England BioLabs, Beverly, MA) and
13 Western blocking reagent. Blots were washed in TBS-T (three
rinses, 5 min each), and then developed with Super Signal (Pierce) and
imaged with a Lumi-imager (Roche Molecular Biochemicals).
For Cox-2 Western analysis, peritoneal macrophages (in RPMI, 5%
FBS) were seeded into 6-well plates (1 3 106 cells/well) and incubated
overnight at 37 °C in a 5% CO2 environment. Cells were washed twice
with RPMI, 5% FBS and then 1 ml of medium containing 100 ng/ml LPS
(type 055:B5, Sigma) was added to each well and the cells were incu-
bated at 37 °C for 4 h. Medium supernatants then were discarded, the
adherent cells were washed twice with PBS, and then they were solu-
bilized by addition of 200 ml of 23 Laemmli sample buffer; the resulting
samples were boiled for 3 min. 20 ml of each sample were fractionated
on a 4–20% Tris-glycine gel, after which the proteins were transferred
to nitrocellulose. These blots were processed as described above except
that the primary antibody employed was anti-prostaglandin synthase-2
(Oxford, Oxford, MI; 1:2000 dilution) and the secondary antibody was
horseradish peroxidase-conjugated rabbit anti-IgG (New England Bio-
Labs, 1:2000 dilution).
YoPro Yellow Uptake—Peritoneal macrophages were washed with
isotonic medium (15 mM Hepes, pH 7.2, 135 mM NaCl, 5 mM KCl, 1.8 mM
CaCl2, 0.8 mM MgCl2) by centrifugation, and the resulting cell pellet
was suspended in isotonic medium to achieve a final cell concentration
of 1 3 106 cells/ml. 50 ml of this cell suspension then was placed into
wells of a Microfluor “B” U-bottom plate (Dynatech, Chantilly, VA), and
50 ml of 2 mM YoPro Yellow (Molecular Probes, Eugene, OR) was intro-
duced; the fluorescent dye was dissolved in isotonic medium. Each well
then was adjusted to 5 mM ATP or 0.0075% saponin by addition of
concentrated stock solutions of these agents. Fluorescence was moni-
tored as a function of time at 37 °C; excitation, 450 nm; emission,
530 nm.
Stimulus-induced IL-1b Post-translational Processing in Vitro—
Macrophages from wild-type and P2X7R
2/2 animals (2 3 106 cells
seeded per well of 6-well cluster plates) were stimulated with 1 mg/ml
LPS for 75 min and then rinsed with 2 ml of methionine-free RPMI
medium containing 100 units/ml penicillin, 100 mg/ml streptomycin, 1%
dialyzed FBS, 1 mg/ml LPS, and 25 mM Hepes, pH 7.3 (pulse medium).
One ml of pulse medium containing 83 mCi/ml of [35S]methionine (Am-
ersham Pharmacia Biotech) then was added to each well, and the cells
were labeled at 37 °C for 1 h. These labeled cells subsequently were
rinsed twice with RPMI 1640 medium containing 100 units/ml penicil-
lin, 100 mg/ml streptomycin, 1% FBS, 2 mM glutamine, 1 mg/ml LPS,
and 25 mM Hepes, pH 7.3 (chase medium). One ml of chase medium
containing no effector, 5 mM ATP, or 20 mM nigericin then was added to
each well, and the cells were chased at 37 °C for 30 min. Media were
harvested and clarified by centrifugation (6000 3 g for 5 min) to remove
cells and/or cell debris. Cell monolayers were suspended in 1 ml of a
lysis buffer composed of 1% Triton X-100, 150 mM NaCl, 25 mM Hepes,
pH 7, 0.1 mM phenylmethylsulfonyl fluoride, 1 mg/ml ovalbumin, 1 mM
iodoacetic acid, 1 mg/ml pepstatin, and 1 mg/ml leupeptin. Clarified
medium samples were adjusted to the same final Triton X-100 and
protease inhibitor concentrations by addition of concentrated stocks of
these reagents. After a 30-min incubation on ice, all samples were
clarified by centrifugation at 45,000 rpm for 30 min in a TLA-45 rotor
(Beckman). The resulting supernatants were recovered and IL-1b was
immunoprecipitated from these samples using a goat anti-murine IL-1b
serum obtained from Dr. Ivan Otterness (Pfizer Central Reseach, Gro-
ton, CT). Immunoprecipitates were fractionated by SDS-gel electro-
phoresis; the quantity of radioactivity associated with individual IL-1b
polypeptide species was determined by scanning dried gels with a
phosphorimager.
ATP-induced IL-1b Post-translational Processing in Vivo—Groups of
mice were injected ip with 1 mg of LPS. Two hours after this LPS
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injection, mice were injected ip with either 0.5 ml of 30 mM ATP
(adjusted to pH 7) or PBS. Mice were euthanized 30 min or 120 min
after the ATP or PBS injection, and each peritoneal cavity was lavaged
with 3 ml of media. Individual lavages were centrifuged, supernatants
were collected and tested by ELISA for the presence of IL-1b (Amer-
sham Pharmacia Biotech) and IL-6 (Endogen, Inc. Woburn, MA). All
procedures involving mice were approved by the Institutional Animal
Care and Use Committee at Pfizer Inc.
RESULTS
Generation and Characterization of P2X7R
2/2 Mice—Mouse
ES cells in which the P2X7R gene was disrupted by homologous
recombination were generated using the scheme shown in Fig.
1. Integration of the targeting vector into the mouse genome by
homologous recombination results in replacement of the region
of the gene encoding Cys506 to Pro532 with the neomycin resist-
ance gene. ES cells containing the mutant P2X7R allele were
identified by Southern blot analysis and used to generate the
P2X7R
D506–532 mouse line. Homozygous null animals were re-
covered in the F2 generation with the expected Mendelian
frequencies. P2X7R
D506–532 (P2X7R
2/2) animals were viable
and fertile and could not be identified among littermates by
observation alone.
Northern analysis of RNA isolated from cultured bone mar-
row mast cells signified that the transcript for the P2X7R was
present in wild-type (1/1) but not knockout (2/2) animals
(Fig. 1C). To further demonstrate that the mutation introduced
into the P2X7R locus resulted in loss of expression of this gene,
peritoneal macrophages obtained from wild-type or P2X7R-
deficient mice were compared by Western analysis for the pres-
ence of the receptor polypeptide. An equivalent number of
macrophages were recovered from wild-type and P2X7R-defi-
cient animals, suggesting that absence of the receptor did not
alter macrophage development. Membranes isolated from wild-
type peritoneal macrophages contained a 76-kDa polypeptide
that cross-reacted with the P2X7R antiserum. The size of the
murine polypeptide is comparable with that displayed by the
human P2X7R when overexpressed in HEK293 cells (Fig. 2). In
contrast, macrophage membranes prepared from cells isolated
from the P2X7R-deficient animals did not contain a similarly
sized polypeptide (Fig. 2). In addition, no smaller cross-reacting
polypeptides were observed in the Western blot of the
P2X7R
2/2 cells, suggesting that the mutation introduced into
the P2X7R gene did not lead to expression of a truncated
version of the receptor (Fig. 2). However, because the antibody
employed was prepared against a peptide epitope that resides
at the extreme carboxyl terminus of the receptor polypeptide,
we cannot exclude the possibility that a truncated form of the
receptor lacking the entire carboxyl terminus is present and
not detected by the analysis.
A hallmark of the P2X7R is its ability to facilitate transloca-
tion of large organic molecules such as the fluorescent dye
YoPro Yellow in response to ATP activation (32, 33, 42, 43).
When mouse peritoneal macrophages isolated from wild-type
animals were activated with 5 mM ATP in the presence of
extracellular YoPro Yellow, a time-dependent increase in fluo-
rescence intensity was observed (Fig. 3). This increase in fluo-
rescence results from internalization of the dye molecules fol-
lowed by their binding to DNA; when bound to DNA, their
fluorescence intensity increases (43). In the absence of ATP, no
FIG. 1. Disruption of the P2X7R gene in ES cells and mice. A,
schematic representation of the P2X7R locus segment, the P2X7R tar-
geting vector, and the targeted P2X7R allele. Filled gray boxes indicate
exons and labeled boxes indicate the PGK-TK and PGK-Neo selection
cassettes. Homologous recombination of the targeting vector with the
endogenous P2X7R gene disrupts the carboxyl-terminal coding region of
the P2X7R gene. Relevant restriction sites are abbreviated as follows: B,
BamHI; RV, EcoRV; K, KpnI; S, SalI. B, detection of targeted and
endogenous P2X7R alleles by Southern blot analysis of DNA from pups
derived from a heterozygous mating. DNA was digested with EcoRV
and hybridized with the probe indicated by a dotted line in A. This probe
detects a 16-kb band from the endogenous locus and a 10-kb band from
the targeted locus. C, total RNA was prepared from cultured bone
marrow-derived mast cells from wild-type (1/1) and P2X7R
2/2 animals
and was assessed by Northern analysis using a cDNA probe specific for
the region that is amino-terminal to the disrupted portion of the P2X7R
gene (corresponding to amino acids Gly313–Leu492). Equal loading of the
lanes and the integrity of the mRNA obtained from the P2X7R
2/2 cells
were confirmed by analysis of the Northern blot with an actin specific
probe.
FIG. 2. Peritoneal macrophages isolated from knockout ani-
mals lack the P2X7R. Membranes isolated from peritoneal macro-
phages (Macs) were fractionated by SDS-polyacrylamide gel electro-
phoresis, and the polypeptides were transferred to nitrocellulose. The
blot then was probed for the presence of the P2X7R. Control lanes
contained membrane proteins isolated from human MRC-5 fibroblasts
(Fb), which do not express P2X7R and membranes recovered from
HEK293 cells transfected with the human P2X7R.
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significant increase in fluorescence intensity was observed,
indicating that YoPro Yellow is impermeable to the plasma
membrane in the absence of the nucleotide triphosphate. In
contrast, addition of ATP to macrophages isolated from
P2X7R
2/2 animals did not result in a time-dependent increase
in fluorescence intensity (Fig. 3). Macrophages isolated from
the P2X7R
2/2 animals demonstrated the same low fluorescence
in the absence and presence of extracellular ATP. In the pres-
ence of saponin, a detergent that permeabilizes the plasma
membrane, YoPro Yellow accumulates to the same extent in
both wild-type and P2X7R
2/2 macrophages (Fig. 3). This dem-
onstrates that the P2X7R mediates ATP-dependent YoPro Yel-
low accumulation.
Stimulus-coupled IL-1b Post-translational Processing—
Peritoneal macrophages isolated from wild-type and P2X7R
2/2
animals were stimulated with LPS and labeled with [35S]me-
thionine. These radiolabeled cells then were chased in the
absence or presence of a secretory stimulus, after which cells
and media were harvested separately, cells were solubilized by
detergent extraction, and IL-1b was recovered from the me-
dium and cell extracts by immunoprecipitation. Radiolabeled
35-kDa pro-IL-1b was recovered from cell extracts derived from
both wild-type and P2X7R
2/2 macrophages (Fig. 4). The
amount of [35S]methionine recovered as the cell-associated 35-
kDa polypeptide (assessed by phosphorimager analysis) after
the chase in the absence of a secretory stimulus was 43,900
PSL/LDH equivalent and 44,100 PSL/LDH equivalent, respec-
tively, from the wild-type and knockout macrophages. This
similarity suggests that the two cell-types generated compara-
ble amounts of pro-IL-1b in response to LPS activation. Neither
the wild-type nor the P2X7R
2/2 macrophages released radiola-
beled IL-1b to the medium in the absence of a secretory stim-
ulus (Fig. 4).
Treatment of LPS-activated [35S]methionine-labeled wild-
type macrophages with extracellular ATP promoted formation
and release of a 17-kDa IL-1b (Fig. 4). Cytokine that remained
cell-associated was for the most part recovered as the 35-kDa
procytokine (Fig. 4). After correcting for the 2-fold loss of ra-
dioactivity that occurs when the 35-kDa procytokine is proteo-
lytically processed by caspase-1 (44), the extracellular 17-kDa
polypeptide represents 64% of the total (sum of cell-associated
and medium species) radiolabeled IL-1b recovered from these
cultures (Fig. 5). In sharp contrast, LPS-activated [35S]methi-
onine-labeled P2X7R
2/2 macrophages did not release any ra-
diolabeled IL-1b to the medium in response to ATP (Fig. 4).
Moreover, cytokine recovered from extracts of the ATP-treated
P2X7R
2/2 macrophages persisted as the 35-kDa procytokine
species (Fig. 4). ATP-treated wild-type but not P2X7R-deficient
macrophages demonstrated enhanced release of LDH relative
to non-ATP treated cultures (Fig. 5B).
In response to the potassium ionophore nigericin, on the
other hand, both wild-type and P2X7R
2/2 macrophages pro-
duced and released a 17-kDa IL-1b (Fig. 4). The extracellular
mature cytokine represented 66 and 74%, respectively, of the
total [35S]methionine-labeled IL-1b recovered from the wild-
type and P2X7R
2/2 cultures (Fig. 5A). Moreover, both macro-
phage populations released comparable quantities of LDH in
response to nigericin (Fig. 5B). Thus, P2X7R
2/2 macrophages
produce pro-IL-1b in response to LPS challenge, and they post-
translationally process this procytokine in response to nigericin
stimulation. However, as a result of the absence of the P2X7R,
these cells do not produce or release mature IL-1b in response
to ATP challenge.
The P2X7R recently was implicated as a component of the
pathway by which LPS induces Cox-2 expression (45). To
determine whether peritoneal macrophages isolated from
FIG. 3. Wild-type but not knockout macrophages accumulate
YoPro Yellow in response to ATP activation. A, peritoneal macro-
phages were incubated with 1 mM YoPro Yellow in the presence (1ATP)
or absence (2ATP) of 5 mM ATP, and resulting fluorescence intensity
changes were recorded as a function of time at 37 °C. B, wild-type and
knockout peritoneal macrophages were incubated with 1 mM YoPro
Yellow in the presence of 0.0075% saponin, and resulting fluorescence
intensity changes were recorded as a function of time.
FIG. 4. P2X7R deficiency abolishes ATP-induced IL-1b post-
translational processing but does not affect nigericin-induced
processes. Peritoneal macrophages were stimulated with LPS for 90
min after which the cells were pulse-labeled with [35S]methionine for 60
min. The radiolabeled cells then were incubated in the absence of any
effector (CON) or presence of 5 mM ATP or 20 mM nigericin (NIG) for 30
min. Cell and media fractions were collected separately, and IL-1b was
recovered from these samples by immunoprecipitation. The immuno-
precipitates were fractionated by SDS-polyacrylamide gel electrophore-
sis, and autoradiograms of the dried gels are shown for the cell-associ-
ated (top) and media (bottom) samples. Arrows indicate the migration
positions of the 35-kDa pro-IL-1b, 17-kDa mature IL-1b, and a 28-kDa




2/2 animals were impaired in their ability to generate
Cox-2 following LPS activation relative to their wild-type coun-
terparts, cultures of the two cell types were stimulated with
LPS and Cox-2 expression was examined by Western analysis.
In the absence of LPS, neither wild-type nor P2X7R
2/2 macro-
phages demonstrated the presence of Cox-2 cross-reacting
polypeptides (Fig. 6). However, after LPS activation, both
macrophage populations possessed a 70-kDa immunogenic
polypeptide (Fig. 6); this is the expected molecular mass of
murine Cox-2 (46).
Characterization of In Vivo Cytokine Production Capabili-
ties—Peritoneal macrophages exposed to LPS in vivo also re-
quire a secretion stimulus to elicit efficient externalization of
mature IL-1b (25). To determine whether absence of the P2X7R
affects IL-1 release in vivo, animals were primed with LPS, and
2 h later they received an ip injection of PBS with or without
ATP. Peritoneal lavage fluids from these animals then were
assessed for IL-1b content by ELISA. Wild-type and heterozy-
gous LPS-primed animals yielded no significant IL-1b in re-
sponse to PBS (Fig. 7), but abundant quantities of IL-1b were
detected following ATP challenge (Fig. 7). In contrast, LPS-
primed P2X7R
2/2 animals failed to generate significant levels
of IL-1b in response to ATP challenge (Fig. 7).
As noted earlier, IL-1 signaling often leads to the production
of other cytokines such as IL-6 (4), and cytokine networks can
be initiated in vivo in response to IL-1 generation. For example,
mice primed with an ip injection of LPS and subsequently
challenged with ATP to promote IL-1 post-translational proc-
essing generate elevated levels of IL-6 compared with animals
challenged with phosphate-buffered saline (25). To determine
whether absence of the P2X7R altered the efficiency of IL-6
production in this type of network response, wild-type and
P2X7R
2/2 animals were compared in a two-stage production
assay format. Animals were administered a priming ip injec-
tion of LPS followed 2 h later by a PBS or ATP challenge.
Peritoneal lavage fluids subsequently were collected at 30 and
120 min, and these were assessed for cytokine content by
ELISA. Wild-type animals primed with LPS and challenged
with PBS or ATP for 30 min yielded 0.05 ng/ml and 0.4 ng/ml
of IL-1b, respectively (Table I). When the time of the challenge
reaction was extended to 2 h, IL-1b levels declined slightly to
0.033 ng/ml in the ATP-treated animals, but levels of IL-1b
within lavage fluids recovered from PBS-challenged animals
remained at the lower limit of detection (Table I). Minimal
levels of IL-1b were recovered from P2X7R
2/2 animals chal-
lenged with PBS or ATP at both the 30 and 120 min time points
(Table I). Quantities of IL-6 generated by wild-type and P2X7R-
deficient animals in response to PBS challenge were compara-
ble at the 30 min harvest, representing 6 and 5 ng/ml, respec-
tively (Table I). After 120 min of PBS challenge, IL-6 levels
declined in both sets of animals to baseline values (Table I).
After 30 min of ATP challenge, both wild-type and P2X7R
2/2
FIG. 5. P2X7R deficiency selectively affects release of mature
IL-1b. A, regions of the gel shown in Fig. 4 containing radiolabeled
IL-1b were scanned by phosphorimager analysis, and the sum of all
species (corrected for the 2-fold loss of radioactivity that occurs when
pro-IL-1 is converted to the 17-kDa species) was determined. The % of
this total that was represented by the 17-kDa species is indicated as a
function of effector treatment. Each bar is an average of duplicate
determinations. B, the amount of LDH released into the medium (ex-
pressed as a % of the total culture-associated activity) is indicated as a
function of effector treatment. Each bar is an average of duplicate
determinations.
FIG. 6. Lack of the P2X7R does not impair Cox-2 expression in
response to LPS stimulation. Peritoneal macrophages from wild-
type (P2X7R
1/1) and knockout (P2X7R
2/2) animals were incubated for
4 h in the absence and presence of LPS, after which cellular polypep-
tides were separated by SDS-polyacrylamide gel electrophoresis. The
presence of Cox-2 subsequently was probed by Western analysis. Each
condition was performed on duplicate cultures. The left lane of the blot
contains standards of the indicated molecular masses.
FIG. 7. P2X7R-deficient peritoneal macrophages fail to gener-
ate IL-1b in response to ATP stimulation in vivo. Wild-type (1/1),
heterozygous (1/2), and homozygous P2X7R-deficient (2/2) mice were
subjected to three different regimens: 1) untreated, 2) ip injection of
LPS followed by a second ip injection of PBS (1LPS/PBS), 3) ip injec-
tion of LPS followed by a second injection of ATP (1LPS/1ATP).
Following these treatments, peritoneal lavage fluids were analyzed for
IL-1b content by ELISA. The amount of IL-1b recovered (ng/ml) is
indicated as a function of treatment. Each bar is the mean 6 S.D. for
five mice.
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animals yielded 8–9 ng/ml of IL-6; these values are slightly
elevated over the quantities of IL-6 recovered from the PBS-
challenged animals at 30 min (Table I). After 120 min of ATP
challenge, on the other hand, wild-type animals yielded higher
levels of IL-6 (17 ng/ml) than the P2X7R
2/2 animals (6 ng/ml)
(Table I). Although levels of IL-6 generated by the ATP-chal-
lenged mutant animals at this time were lower than those
generated by their wild-type counterparts, they were elevated
above those generated in response to PBS challenge (6 ng/ml
when challenged with ATP versus 0 ng/ml when challenged
with PBS; Table I). This suggests that ATP affects IL-6 pro-
duction via both a P2X7R-dependent and -independent mecha-
nism. No IL-1b or IL-6 could be detected in lavage fluids ob-
tained from animals that were primed with saline (data not
shown).
DISCUSSION
Pharmacological evidence suggests that the P2X7R has a
restricted cellular distribution and is expressed primarily on
cells of hematopoietic origin including monocytes, macro-
phages, mast cells, lymphocyte populations, and dendritic cells
(35, 47–51). Several other reports suggest that expression is
not exclusive to this lineage as there is evidence of P2X7R
expression on sperm (52) and some cancer cells of non-hema-
topoietic lineage (53). Despite extensive studies, the physiolog-
ical function of this receptor remains unclear. It has been
reported to participate in a diverse list of cellular activities
including lymphocyte proliferation (54), fertilization (52), giant
cell formation (55), cell death (36, 37), killing of invading my-
cobacteria (56), and IL-1 post-translational processing (20, 22).
In the absence of specific receptor agonists and antagonists,
however, P2X7R participation has generally been inferred
based on ATP concentration requirements and the use of non-
selective antagonists. Following its cloning, overexpression
studies established that the P2X7R is responsible for the ability
of ATP to promote pore formation within the plasma membrane
of cells expressing this receptor (28, 29). These pores allow
passage of large organic molecules such as YoPro Yellow and
ethidium bromide, a feature not shared with other members of
the P2X family of ligand-gated ion channels. Ligation of the
P2X7R also has been associated with activation of phospho-
lipase D and activation of some transcription factors (57–59).
To what extent these reported activities are manifested in vivo
remains to be determined. In this study we report the genera-
tion of a mouse line that fails to express the P2X7R polypeptide.
These P2X7R-deficient mice are healthy and fertile. The ab-
sence of striking phenotypic traits associated with mature
knockout mice suggests that the P2X7R is dispensable for nor-
mal development. Moreover, homozygous male animals are
fertile, suggesting that absence of the P2X7R does not compro-
mise sperm development and function (52). However, although
their macrophages can respond to LPS and promote pro-IL-1b
and Cox-2 expression, the receptor-deficient cells fail to gener-
ate mature IL-1b in response to subsequent ATP challenge. As
a consequence, P2X7R-deficient animals demonstrate an atten-
uated response in a cytokine signaling network in vivo.
Several previous studies demonstrated that overexpression
of the P2X7R led to the ability of ATP to promote pore formation
and fluorescent dye accumulation (28, 29). Macrophages iso-
lated from wild-type, but not from P2X7R
2/2 mice, responded to
extracellular ATP and accumulated YoPro Yellow. Thus, the
knockout provides the corollary to the overexpression experi-
ments; depletion of the receptor leads to an inability to form
pores that facilitate passage of YoPro yellow. These data, how-
ever, do not prove that the P2X7R is the actual pore-forming
polypeptide. BW5147 cells express the murine P2X7R, yet these
cells do not accumulate ethidium bromide in response to ATP
challenge (60). Moreover, the marine toxin maitotoxin activates
P2X7R-like pores in cells that do not express the P2X7R (61).
These observations led to the proposal that the P2X7R itself
may not constitute the pore but, rather, may link to and/or
activate the pore-forming unit (61).
One of the most intriguing activities attributed to the P2X7R
is its ability to induce post-translational processing of pro-IL-1
(18, 20, 22). Data previously have been presented establishing
that efficient release of mature IL-1b from LPS-activated
monocytes and macrophages requires the cytokine-producing
cells to encounter a secretion stimulus. Agents or treatments
that have been shown to function in this capacity in vitro
include ATP, nigericin, hypotonic stress, cytolytic T-cells, and
bacterial toxins (19–24). All of these effectors appear to initiate
IL-1 post-translational processing reactions by inducing
changes to the intracellular ionic environment. For example,
treatment of LPS-activated monocytes with ATP or nigericin
promotes loss of intracellular K1 (22). When this loss is pre-
vented by exposing the cells to the secretion stimuli in the
presence of elevated extracellular K1 concentrations, IL-1b
post-translational processing is completely inhibited (18, 22,
62). Therefore, depletion of intracellular K1 appears to be a
necessary element of the stimulus-induced process. Likewise,
inhibitors of anion transport, such as tenidap, ethacrynic acid,
and glyburide, disrupt ATP-induced IL-1b post-translational
processing suggesting that anion movements are a necessary
feature of the cellular process (17, 26, 63).
Peritoneal macrophages isolated from the P2X7R
2/2 mice
responded to LPS activation and produced quantities of pro-
IL-1b and Cox-2 comparable with those produced by wild-type
macrophages. Although we cannot rule out the possibility of
the involvement of a compensatory mechanism, these data
suggest that the P2X7R is not required for induction of LPS-
inducible gene products. In contrast to our findings, a previous
study concluded that ATP released from macrophages as a
result of LPS activation served as an autocrine-type stimulus
TABLE I
P2X7 receptor-deficient mice generate less IL-6 in response to LPS/ATP challenge
Wild-type (WT) and P2X7R
2/2 mice were primed with an ip injection of LPS, and 2 hr later these animals were challenged with an additional
ip injection of PBS or ATP. At 30- and 120-min post-challenge, separate animals were sacrificed, and peritoneal lavages were collected; cytokine
content within the clarified lavage fluids subsequently was assessed by ELISA. Each indicated value is the mean and where indicated S.D. of six
separate animals. The limit of detection of the ELISAs, based on comparison of the assay response to recombinant cytokine standards, was 0.05
ng/ml for the IL-1 kit and 0.05 ng/ml for the IL-6 kit.
Time post-challenge
PBS Challenge ATP Challenge






min ng/ml ng/ml ng/ml ng/ml
30 0.05 0.04 5.6 6 0.7 4.7 6 0.6 0.4 6 0.12 0.04 8.2 6 1.7 9 6 1
120 0.02 0.02 1 6 0.6 0 0.33 6 0.08 0.02 16.8 6 2.3 5.7 6 1.2
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to promote expression of Cox-2 via ligation of the P2X7R (45).
Conclusions reached in this previous study, however, were
based on the use of non-selective inhibitors of the P2X7R, and
these compounds may elicit their effects by disrupting other
cellular processes. Although expression of pro-IL-1b was nor-
mal in macrophages that lacked the P2X7R, post-translational
processing of the procytokine in response to ATP challenge was
totally ablated. Therefore, the P2X7R is a necessary element of
the post-translational processing mechanism. Interestingly,
LPS-activated P2X7R-deficient macrophages continued to pro-
duce mature IL-1b in response to nigericin challenge. Nigeri-
cin, therefore, must promote cytokine post-translational proc-
essing independently of the P2X7R. The mechanisms by which
nigericin and ATP initiate pro-IL-1b post-translational proc-
essing appear to share common elements. For example, both
mechanisms require extracellular Na1 (62), both are inhibited
by high extracellular K1 (22), and both result in similar mor-
phological transformations (22). Perhaps, these two diverse
stimuli link to a common pore-forming subunit to initiate the
cytokine production pathway.
IL-1 is known to elicit complex cytokine signaling networks
when administered to animals, and injection of the recombi-
nant cytokine locally within animal joints can lead to an in-
flammatory response and attendant structural changes that
mimic the pathophysiological process taking place in joints of
patients suffering from rheumatoid arthritis (Ref. 64). Many
gene products are known to be up-regulated in response to IL-1
signaling including IL-6 (4). Ip injection of LPS into wild-type
mice produced no extracellular IL-1b and only small quantities
of IL-6. However, following challenge with extracellular ATP,
these LPS-primed mice generated cell-dissociated IL-1b and, in
turn, much greater levels of IL-6. In contrast, LPS-primed
P2X7R
2/2 animals failed to generate IL-1 in response to ATP
challenge and failed to match the large increase in IL-6 pro-
duction demonstrated by their wild-type counterparts. These
observations indicate that IL-1 released as a result of the
P2X7R can serve as a functional element of a cytokine network.
Although the ATP-dependent IL-6 response of the knockout
animals was greatly attenuated relative to the wild-type, the
knockout animals did appear to respond to ATP. LPS-primed
P2X7R
2/2 animals that were subsequently challenged with
PBS yielded no significant IL-6 at 4-h post-LPS priming. On
the other hand, comparable animals challenged with ATP
yielded 6 ng/ml of IL-6 at the 4-h time point. This suggests that
ATP may work through other purinoceptors to affect IL-6 pro-
duction. Perhaps ATP activation of G-protein-coupled P2Y-type
receptors leads to changes in intracellular cAMP and/or Ca21
that enhance the LPS-induced IL-6 production response (48).
Additional work will be required to understand this P2X7R-
independent response, and studies are ongoing to further char-
acterize in vivo inflammatory processes within the receptor-
deficient mice to gain a more complete understanding of how
absence of this receptor affects immune system function.
IL-1 is a potent mediator of inflammatory responses (1). Not
surprisingly perhaps, animals appear to have developed a
number of safeguards to ensure that IL-1 activity is tightly
regulated. For example, a natural receptor antagonist, IL-1ra,
exists and this protein competes with IL-1 for binding to the
type-1 IL-1 receptor (65). Unlike IL-1a and IL-1b, IL-1ra bind-
ing does not lead to receptor activation. Rather, the receptor
antagonist appears to be produced via an endogenous process
to suppress IL-1 signaling events. Another safeguard exists in
the type-2 IL-1 receptor. Binding of IL-1 to this receptor does
not initiate signaling cascades within target cells (66). Rather,
the type-2 receptor appears to act as a decoy and provides a
mechanism to buffer and/or blunt an IL-1 biologic response.
Finally, the unique post-translational requirements of IL-1
appear to offer yet an additional safeguard. Monocytes and
macrophages may become activated to produce the procytokine
polypeptides, but these remain latent unless the producing
cells encounter a secondary stimulus that promotes their post-
translational processing and release. The P2X7R
2/2 mice es-
tablish that ATP acting through the P2X7R represents one
potential mechanism by which IL-1 post-translational process-
ing is achieved in vivo. Understanding how P2X7R activity
is regulated, therefore, may provide important insights for
designing strategies to control inflammatory response
mechanisms.
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